Sign in
CLRB Stock Price, Chart, Stats & News
Cellectar Biosciences, Inc.
Save
8.25M
Market cap
–
Current P/E
–
Forward P/E
CLRB chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -145.48% |
ROE | -248.91% |
D/E | 0.04x |
Interest coverage ratio | – |
CLRB valuation
P/E | – |
P/S | – |
P/B | 1.15x |
P/CF | -0.50x |
P/FCF | -0.37x |
P/OCF | -0.50x |
PEG | -0.13x |
EV multiple | -0.96x |
About
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.
Similar securities
Based on sector and market capitalization
Report issue